Search research articles
Contact Us
Filters
Showing results (71-80 of 139) with videos related to
Page
of 14
Sort By:
Pediatrics
|
June 9, 2026
Use of Leucovorin After the FDA Announcement of Its Use for Autism Spectrum Disorders
Benjamin N Rome, John Kim, Jose F Figueroa, et al.
JAMA Internal Medicine
|
January 30, 2023
Estimated Medicaid Spending on Original and Citrate-Free Adalimumab From 2014 Through 2021
Junyi Wang, ChangWon C Lee, Aaron S Kesselheim, et al.
Pharmacoepidemiology and Drug Safety
|
October 13, 2024
Use of Omalizumab for Pediatric Asthma After US Food and Drug Administration Expanded Indications
Anjali D Deshmukh, Aaron S Kesselheim, Theodore Tsacogianis, et al.
Annals of Internal Medicine
|
April 29, 2024
Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label
Alexander C Egilman, Aaron S Kesselheim, Ameet Sarpatwari, et al.
JAMA Internal Medicine
|
March 9, 2026
Cost-Related Medication Nonadherence After the Inflation Reduction Act
Lucas X Marinacci, Stephen Mein, Benjamin N Rome, et al.
JAMA
|
May 14, 2025
Insurer Exits After the Inflation Reduction Act Part D Redesign
Christopher L Cai, Aaron S Kesselheim, Anushka Bhaskar, et al.
The New England Journal of Medicine
|
October 11, 2023
Will Medicare Price Negotiation Delay Cancer-Drug Launches?
Matthew Vogel, Aaron S Kesselheim, William B Feldman, et al.
JAMA Internal Medicine
|
August 18, 2025
Changes in Medicare Part D Plan Designs After the Inflation Reduction Act
Christopher L Cai, Anushka Bhaskar, Aaron S Kesselheim, et al.
The New England Journal of Medicine
|
January 13, 2021
The Future of Drug-Pricing Transparency
William B Feldman, Benjamin N Rome, Jerry Avorn, et al.
JAMA Internal Medicine
|
March 29, 2021
Frequency of First Generic Drug Approvals With "Skinny Labels" in the United States
Bryan S Walsh, Ameet Sarpatwari, Benjamin N Rome, et al.
Page
of 14
Search research articles
Search
Showing results (71-80 of 139) with videos related to
Sort By:
Page
of 14
Pediatrics
|
June 9, 2026
Use of Leucovorin After the FDA Announcement of Its Use for Autism Spectrum Disorders
Benjamin N Rome, John Kim, Jose F Figueroa, et al.
JAMA Internal Medicine
|
January 30, 2023
Estimated Medicaid Spending on Original and Citrate-Free Adalimumab From 2014 Through 2021
Junyi Wang, ChangWon C Lee, Aaron S Kesselheim, et al.
Pharmacoepidemiology and Drug Safety
|
October 13, 2024
Use of Omalizumab for Pediatric Asthma After US Food and Drug Administration Expanded Indications
Anjali D Deshmukh, Aaron S Kesselheim, Theodore Tsacogianis, et al.
Annals of Internal Medicine
|
April 29, 2024
Estimated Medicare Part D Savings From Generic Drugs With a Skinny Label
Alexander C Egilman, Aaron S Kesselheim, Ameet Sarpatwari, et al.
JAMA Internal Medicine
|
March 9, 2026
Cost-Related Medication Nonadherence After the Inflation Reduction Act
Lucas X Marinacci, Stephen Mein, Benjamin N Rome, et al.
JAMA
|
May 14, 2025
Insurer Exits After the Inflation Reduction Act Part D Redesign
Christopher L Cai, Aaron S Kesselheim, Anushka Bhaskar, et al.
The New England Journal of Medicine
|
October 11, 2023
Will Medicare Price Negotiation Delay Cancer-Drug Launches?
Matthew Vogel, Aaron S Kesselheim, William B Feldman, et al.
JAMA Internal Medicine
|
August 18, 2025
Changes in Medicare Part D Plan Designs After the Inflation Reduction Act
Christopher L Cai, Anushka Bhaskar, Aaron S Kesselheim, et al.
The New England Journal of Medicine
|
January 13, 2021
The Future of Drug-Pricing Transparency
William B Feldman, Benjamin N Rome, Jerry Avorn, et al.
JAMA Internal Medicine
|
March 29, 2021
Frequency of First Generic Drug Approvals With "Skinny Labels" in the United States
Bryan S Walsh, Ameet Sarpatwari, Benjamin N Rome, et al.
Page
of 14